Drugs / EXS21546
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04727138 | Dec 2020 → Apr 2022 | — | Exscientia AI Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05920408 | Apr → Sep 2023 | neoplasm | Exscientia AI Limited | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXS21546 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04727138 ↗ |
| Route | Oral | “EXS21546 Powder for Oral Suspension” NCT04727138 ↗ |